Based on human and preclinical studies , we hypothesized that a combination of low-dose anti-thymocyte globulin ( ATG ) and pegylated granulocyte CSF ( G-CSF ) would preserve cell function in patients with established T@D ( duration of T@D > @ months and < @ years ) .